Advertisement
Advertisement
URGN
UroGen Pharma Ltd. Ordinary Shares
24.75
USDSponsored
-0.98
-3.81%
Nov 06, 15:59 UTC -5
Closed
After-Market
24.68
-0.07
-0.26%
UroGen Pharma Ltd. Ordinary Shares (URGN) Earnings
URGN Earnings Reports
Positive Surprise Ratio
URGN beat 18 of 38 last estimates.
47%
Next Report
Date of Next Report
Mar 01, 2027
Estimate for Q4 26 (Revenue/ EPS)
$110.76M
/$0.51
Implied change from Q3 26 (Revenue/ EPS)
+24.45%
/-1800.00%
Implied change from Q4 25 (Revenue/ EPS)
+192.74%
/-194.44%
UroGen Pharma Ltd. Ordinary Shares earnings per share and revenue
On Nov 04, 2026, URGN reported earnings of -0.03 USD per share (EPS) for Q3 26, missing the estimate of 0.13 USD, resulting in a -121.79% surprise. Revenue reached 89.00 million, compared to an expected 91.72 million, with a -2.96% difference. The market reacted with a -16.45% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.51 USD, with revenue projected to reach 110.76 million USD, implying an decrease of -1800.00% EPS, and increase of 24.45% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were UroGen Pharma Ltd. Ordinary Shares's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, UroGen Pharma Ltd. Ordinary Shares reported EPS of -$0.03, missing estimates by -121.79%, and revenue of $89.00M, -2.96% below expectations.
How did the market react to UroGen Pharma Ltd. Ordinary Shares's Q3 2026 earnings?
The stock price moved down -16.45%, changed from $34.40 before the earnings release to $28.74 the day after.
When is UroGen Pharma Ltd. Ordinary Shares expected to report next?
The next earning report is scheduled for Mar 01, 2027.
What are the forecasts for UroGen Pharma Ltd. Ordinary Shares's next earnings report?
Based on --
analysts, UroGen Pharma Ltd. Ordinary Shares is expected to report EPS of $0.51 and revenue of $110.76M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.